Abstract Obstructive sleep apnea syndrome (OSAS) is an often underestimated sleep disorder that has been associated with cardiovascular disease. OSAS is characterized by cycles of apnea and/or hypopnea during sleep caused by the collapse of the upper airways. Intermittent hypoxia deriving from the cycles of apnea/arousals (to retrieve the ventilation) plays a pivotal role in the pathogenesis of the disease. Obesity is the most frequent predisposing condition of OSAS. Recent evidence suggests that OSAS could be considered as a pro-atherosclerotic disease, independently of visceral fat amount. Oxidative stress, cardiovascular inflammation, endothelial dysfunction, and metabolic abnormalities in OSAS could accelerate atherogenesis. The present review is focused on the possible pathophysiological mediators which could favor atherosclerosis in OSAS.
Introduction
Sleep apnea is an underdiagnosed syndrome, characterized by periods of breathing apnea and/or a marked reduction of the tidal volume (hypopnea) occurring during sleep. Obstructive sleep apnea syndrome (OSAS) is caused by the collapse of the upper airways. OSAS patients manifest excessive daytime sleepiness related to the fragmentation of the sleep by frequent arousal, which might favor the development of cognitive dysfunction and memory loss because of cerebral hypoxemia [1, 2] . Although it is still considered as a local and upper airway disorder, OSAS is now deemed a systemic disease that could involve not only the respiratory but also central nervous and cardiovascular systems. Intermittent hypoxemia (IH, intermittent periods of oxygen saturation below 90%) can increase oxidative stress, pro-inflammatory cytokine production, platelet aggregation, and metabolic dysregulation [1, [3] [4] [5] . Importantly, sleep-related IH was independently associated with all-cause mortality in 6,441 men and women participating in the Sleep Heart Health Study [6] . Several studies have demonstrated the association of OSAS with arterial hypertension [7, 8] , stroke [9] [10] [11] [12] , coronary artery disease (CAD) [13] [14] [15] [16] , or pulmonary hypertension [17] . Sleep-disordered breathing was also significantly associated with coronary artery disease-related mortality [6] . The high mortality risk in untreated sleep-disordered breathing has been shown as independent of age, sex, and body mass index (BMI) [18] . Thus, recent evidence showed that OSAS should be considered as a condition predisposing cardiovascular disease [2, 15, [19] [20] [21] . Nevertheless, the elevated incidence of OSAS in the adult population (4% men and 2% women between 30 and 60 years of age manifest the severe form of the disorder, while these percentages go up to 5-15% considering all stages of the disease) [22] [23] [24] and the risk of severe systemic complications confer to the diagnosis and treatment of OSAS a remarkable social importance.
OSAS-associated cardiovascular inflammation and its clinical relevance will be discussed in the present article.
Clinical relevance of OSAS
OSAS represents a systemic worldwide disease, mainly affecting obese subjects (up to 70% of OSAS patients are obese). This association renders difficult to define OSAS impact as an independent factor of risk [25, 26] .
Subjects with OSAS have an increased comorbidity (CAD, stroke, arterial hypertension) and mortality, while continuous positive airway pressure (CPAP) treatment seems to improve survival [27, 28] . Marshall and coworkers recently showed that moderate to severe OSAS is independently associated with an increased risk of all-cause mortality in 397 residents of Busselton town (Western Australia) after up to a 14-year follow-up [29] . Doherty and co-workers observed that deaths for cardiovascular disease were more common in the untreated group of patients than in the CPAP-treated one during follow-up (14.8% vs. 1.9%, respectively) [30] . Cross-sectional associations from the Sleep Heart Health Study cohort (6,424 subjects) demonstrated that OSAS induces only modest to moderate effects on cardiovascular disease [15] . On the other hand, OSAS has high incidence among persons with known CAD (30-58%) [31, 32] . The relative risk for myocardial infarction in OSAS subjects for the upper quartile of the apnea index has been shown to be 23.3 compared with the lowest quartile, indicating a strong association between OSAS and the acute coronary syndrome. These studies suggest that OSAS is an independent risk factor for CAD [14] . Subjects with coexistent OSAS and CAD have higher mortality (38% vs. 9%), increased rate of restenose after percutaneous coronary intervention (24% vs. 5%), and increased rate of major adverse cardiac events (37% vs. 15%) as compared to CAD patients without OSAS [33] . Recent studies have shown early atherosclerotic lesions in OSAS subjects (such as the increase of intima-media thickness [IMT]), which can be reduced by CPAP treatment [34] [35] [36] . Furthermore, IMT is significantly correlated to levels of C-reactive protein (CRP), interleukin (IL)-6, and severity of OSAS [35] . OSAS is also associated with other signs of early atherosclerosis, such as increased arterial stiffness and heart remodeling (increased left atrial diameter, interventricular septal thickness, and left ventricle mass index), independently of other confounding factors [34, 37] .
In the last decades, increasing evidence showed that OSAS is also associated with arterial hypertension [8, [38] [39] [40] . Large clinical studies have demonstrated that OSAS is an independent risk factor for hypertension [7, 20, 41] with an adjusted odds ratio for baseline hypertension, non-modifiable risk factors, obesity, and smoke of 2.9 [20] . Several studies have also demonstrated that CPAP treatment not only reduces nocturnal blood pressure [42] but also decreases daytime diastolic blood pressure [43] [44] [45] . On the other hand, some authors failed to find any beneficial effect on blood pressure when investigating hypertensive OSAS patients [46] .
OSAS has been also related to an increased risk of stroke. The Sleep Heart Health Study showed a small but significant increase in stroke prevalence among OSAS subjects [15] . Yaggi and co-workers showed that OSAS subjects have a 2-fold increased risk of stroke as compared with non-OSAS subjects in a 3.5-year follow-up [12] . Moreover, OSAS is associated with a more serious prognosis after stroke [11, 47] .
Other known cardiovascular complications are different types of arrhythmias (brady-and tachyarrhythmias) [48, 49] , pulmonary hypertension [50-52], and congestive heart failure [53, 54] .
The nasal CPAP is the gold-standard treatment; it significantly improves oxygen saturation and general symptoms. In spite of the existing debate, some studies have shown that CPAP reduces the levels of systemic inflammatory markers such as TNF-α, IL-6, CRP, and IL-8 [55] [56] [57] [58] .
Several pathogenetic mechanisms have been proposed to explain the possible association between OSAS and cardiovascular disease.
Cardiovascular inflammation in OSAS
Oxidative stress IH is a key element in the pathophysiology of OSAS and its complications. It consists of cycles of short periods of oxygen desaturation followed by retrieval of the ventilation with normalized oxygenation. It has been postulated that IH is a harmful mechanism analogous to ischemia-reperfusion injury. In ischemia-reperfusion injury, the damage occurs when the blood flow to an ischemic or hypoxic tissue is restored [1, 3, 5, 59 , 60] and overproduction of reactive oxygen species (ROS) is induced. The same mechanism might be implicated in intermittent hypoxia during sleep. During reperfusion, ROS are generated through the xanthine oxidase pathway, the NADPH oxidase pathway, and the incomplete oxidative phosphorylation in the mitochondria [22, [61] [62] [63] ROS production is associated with the upregulation of different genes regulated by the pro-inflammatory nuclear factor kappa B (NF-κB) pathway [3, 72, 73] . NF-κB mediates the production of inducible NO synthase (iNOS) [74] and cyclooxygenase (COX)-2. NF-κB also activates the overexpression of adhesion molecules involved in leukocyte recruitment and migration to the inflammatory site, i.e., intercellular adhesion molecule-1 (ICAM-1), Eselectin, and vascular cell adhesion molecule-1 (VCAM-1) [73, 75, 76] . Accordingly, NF-κB is highly activated in OSAS patients as compared to healthy controls. Furthermore, CPAP treatment strongly reduces NF-κB activation [77] . Interestingly, IH does not seem to activate protective hypoxia-inducible factor-1 (HIF-1), a key regulator of the adaptive pathway to chronic hypoxia [72, 78] . The short duration of hypoxia in IH does not allow the stabilization of HIF-1 and the cyclic re-oxygenation induces mitochondria dysfunction. Thus, it results in the activation of the NF-κB pathway alone [78, 79] . These results are controversial and need further confirmations. Indeed, it is well known that HIF-1 downstream proteins, such as the vascular endothelial growth factor (VEGF, which regulates the oxygen homeostasis), iNOS, and endothelin-1 (a potent vasoconstrictor), are increased in OSAS, suggesting a possible activation of HIF-1 pathway [80-87].
Systemic inflammatory mediators
Several evidences suggest that OSAS might be considered as a systemic inflammatory disease ( Table 1 ). The levels of the pro-inflammatory cytokine TNF-α are correlated with the severity of OSAS. TNF-α modulates physiological sleep [88] [100] . The alteration of CRP levels in OSAS obese patients remains controversial, mainly because of the relationship between CRP and BMI [101] . Nevertheless, studies showed that in OSAS subjects, CRP levels are independently associated with the severity of the disease [35, 55, 58, 69, [102] [103] [104] [105] [106] [107] [108] . Importantly, 1-month treatment with CPAP significantly reduces CRP levels. More recently, increased levels of CRP were associated with OSAS in obese men independently of adiposity [109] . CRP levels also correlate with the degree of nocturnal hypoxemia independently of obesity [110] . Larkin and co-workers recently showed that an AHI ≥5 is associated with increased CRP serum levels in adolescents without known cardiovascular diseases. The relationship between CRP and sleep-disordered breathing was also confirmed after adjustment of important covariates (including BMI, hypertension, waist-to-hip ratio, and lipid profile) [104] . Conversely, these interesting associations were not confirmed by other studies [96, [111] [112] [113] [114] [115] [116] . Larger and controlled studies are needed to better understand the role of CRP-mediated effects in the OSAS pathophysiology. [118, 119] . In particular, increased serum levels of leukocyte proteases (such as matrix metalloproteinase [MMP]-9) have been found in OSAS [120] .
A relationship between the acute phase reactant serum amyloid A (SAA) and the degree of OSAS has been also shown. Furthermore, SAA levels have been reduced by CPAP treatment [121] .
Leptin is the product of the obese gene in the adipocytes and mediates several functions such as the regulation of food intake, the energy balance, and the regulation of lipid and glucose metabolism [122, 123] . In obesity (a condition known as leptin resistance), leptin levels are increased [124, 125] . Leptin activates inflammation and mediates cellular damage synergistically with IH in a rabbit model of OSAS [78] . Although the major inducing factor for leptin production is visceral obesity [112] , hypoxia might increase leptin production [126] [127] [128] . Furthermore, leptin correlates with OSAS independently of obesity [129] [130] [131] [132] [133] . Kapsimalis and co-workers confirmed that nocturnal hypoxemia is associated with leptin independently of obesity [112] . Conversely, other studies did not show a significant association between leptin levels and OSAS after adjustment for obesity [134] [135] [136] [137] .
Homocysteine is a product of the metabolism of the aminoacid methionine and increases the risk of arterial occlusive disease [138] causing endothelial dysfunction [3, [139] [140] [141] . Controversial data have been reported on homocysteine levels in OSAS. Some studies indicate that homocysteine is increased in OSAS subjects with cardiovascular disease (CAD) in comparison with OSAS subjects without CAD and with healthy controls [102, 142] . Accordingly, CPAP treatment reduces homocysteine concentrations [143] . Conversely, other studies did not confirm this association [62, 144] . Finally, studies on insulin [110, [145] [146] [147] and adiponectin [132, [147] [148] [149] [150] also showed controversial results. Further studies are needed to better address the role of these inflammatory cardiovascular risk markers in OSAS.
Endothelial dysfunction
Endothelium regulates the vascular tone and maintains the pro-/anti-inflammatory equilibrium in the vessel wall. Alterations of the normal homeostasis of the vascular wall represent early signs of cardiovascular diseases [151] . Recent studies have demonstrated that OSAS significantly affects the endothelial function. Indeed, endothelium-dependent vasodilation in response to acetylcholine is reduced in OSAS patients in comparison with age-and BMI-matched healthy subjects [152, 153] . Flow-mediated vasodilation is impaired in OSAS with a direct correlation with the severity of the hypoxemia [154] . The normal function of the endothelium depends on the bioavailability of NO. In OSAS, reduced levels of circulating NO [155, 156] and elevated concentrations of endothelial NO synthase inhibitor have been shown, as compared to healthy controls [157] .
The mechanisms by which OSAS might affect the endothelial function are dependent on IH and sleep fragmentation [158] . As mentioned above, IH causes a reduction of NO production by affecting the transcriptional and post-transcriptional pathways and by increasing the production of ROS. ROS could react with NO, further reducing its availability and enhance the oxidative stress. Moreover, IH up-regulates cyclooxygenase-2 (COX-2), VEGF, endothelin-1, and iNOS, which might further alter the functional integrity of the endothelium [80-87]. Sleep fragmentation is associated with 50% reduction of the flowmediated vasodilation [159] . Several studies show increased inflammation, activation of the sympathetic tone, and hypercoagulability during repetitive arousals from sleep during OSAS [160] [161] [162] . Accordingly, treatment with CPAP reverses endothelial dysfunction [163] .
Endothelial dysfunction could be a key element in atheroprogression in OSAS. Further efforts should be done in order to better understand and possibly prevent endothelial dysfunction in OSAS.
Conclusions
Despite its underestimation, OSAS should be considered a serious disease involving not only the respiratory system but also having cardiovascular and cerebral implications. The promotion of atherogenesis through oxidative stress, inflammation, and endothelial dysfunction is still a matter of debate. Intermittent hypoxia is the distinctive element of OSAS and could play a pivotal role in triggering cardiovascular inflammation. The treatment with CPAP represents a very promising therapeutic strategy to clinically improve OSAS and reduce the associated oxidative stress, cardiovascular inflammation, and endothelial dysfunction. Larger randomized clinical studies are still needed to identify more selective cardiovascular risk markers in OSAS. 
